Vanguard Group Inc. Sells 92,866 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Vanguard Group Inc. lessened its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 2.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,902,479 shares of the company's stock after selling 92,866 shares during the period. Vanguard Group Inc. owned about 8.05% of Axsome Therapeutics worth $330,189,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of AXSM. FMR LLC increased its position in shares of Axsome Therapeutics by 20.6% in the third quarter. FMR LLC now owns 1,088,087 shares of the company's stock worth $97,786,000 after acquiring an additional 185,951 shares in the last quarter. Geode Capital Management LLC lifted its position in Axsome Therapeutics by 2.7% in the 3rd quarter. Geode Capital Management LLC now owns 908,459 shares of the company's stock worth $81,659,000 after buying an additional 23,564 shares in the last quarter. Wellington Management Group LLP raised its holdings in shares of Axsome Therapeutics by 1.1% during the third quarter. Wellington Management Group LLP now owns 742,745 shares of the company's stock worth $66,750,000 after acquiring an additional 8,125 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Axsome Therapeutics by 1.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 328,034 shares of the company's stock worth $27,755,000 after purchasing an additional 5,438 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in Axsome Therapeutics by 14.9% in the third quarter. JPMorgan Chase & Co. now owns 212,110 shares of the company's stock valued at $19,062,000 after acquiring an additional 27,534 shares during the last quarter. 81.49% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Axsome Therapeutics Trading Up 2.5 %

NASDAQ AXSM traded up $2.50 during trading on Tuesday, reaching $101.00. 98,625 shares of the stock traded hands, compared to its average volume of 664,774. The stock's 50-day moving average price is $120.54 and its 200 day moving average price is $101.85. The company has a quick ratio of 2.04, a current ratio of 2.11 and a debt-to-equity ratio of 3.22. The firm has a market cap of $4.93 billion, a price-to-earnings ratio of -16.86 and a beta of 0.88. Axsome Therapeutics, Inc. has a fifty-two week low of $64.11 and a fifty-two week high of $139.13.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last released its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) EPS for the quarter, beating analysts' consensus estimates of ($0.97) by $0.01. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%. The business had revenue of $118.77 million during the quarter, compared to analysts' expectations of $117.83 million. Analysts predict that Axsome Therapeutics, Inc. will post -2.79 EPS for the current year.

Insider Activity at Axsome Therapeutics

In other news, CFO Nick Pizzie sold 3,000 shares of the business's stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $131.07, for a total value of $393,210.00. Following the sale, the chief financial officer now directly owns 42,187 shares in the company, valued at $5,529,450.09. The trade was a 6.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 22.40% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Bank of America lifted their target price on Axsome Therapeutics from $143.00 to $167.00 and gave the stock a "buy" rating in a research report on Tuesday, February 11th. Jefferies Financial Group started coverage on Axsome Therapeutics in a research report on Monday. They set a "buy" rating and a $200.00 price objective on the stock. Wells Fargo & Company raised their target price on Axsome Therapeutics from $140.00 to $160.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 12th. HC Wainwright reaffirmed a "buy" rating and set a $200.00 price objective on shares of Axsome Therapeutics in a report on Thursday, April 3rd. Finally, Truist Financial lifted their price target on shares of Axsome Therapeutics from $190.00 to $200.00 and gave the company a "buy" rating in a report on Wednesday, February 19th. One equities research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $169.80.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.